Curriculum Vitae

Download a PDF version.



President, Michigan State University


Place of birth: Seattle, Washington
Spouse: Ellen Li, M.D., Ph.D.




Office of the President
Michigan State University
426 Auditorium Road
Hannah Administration Building, Room 450
East Lansing, MI 48824-1046

Phone: (517) 355-6560


Year(s) Education
1976 B.A., Biological Sciences, The College of the University of Chicago, IL
1980 M.D., Medicine, Harvard University Medical School, Cambridge, MA
1984-1987 Postdoctoral, Immunology, Washington University School of Medicine, St. Louis, MO


Year(s) Position
1976 Teaching Assistant in Biology, The College of the University of Chicago, IL
1980-1981 Medical Intern, Massachusetts General Hospital, Boston, MA
1981-1983 Medical Resident, Massachusetts General Hospital, Boston, MA
1983-1984 Fellow in Infectious Diseases, Washington University School of Medicine, St. Louis, MO
1985-1988 Pfizer Fellow in Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO
1987-1988 Instructor in Medicine, Washington University School of Medicine, St. Louis, MO
1988 Assistant Professor, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO
1989 Assistant Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO
1990-2009 Chief Medical Consultant, BarnesCare Travelers Clinic
1993-1999 Associate Professor (with tenure), Department of Medicine, Washington University School of Medicine, St. Louis, MO
1994-2004 Associate Professor, Department of Molecular Microbiology
1999-2009 Professor, Department of Medicine, Washington University School of Medicine, St. Louis, MO
2003-2009 Director, Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research
2004-2009 Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO
2006-2009 Vice Chancellor for Research, Washington University in Saint Louis, MO
2009-2019 Professor of Medicine, Stony Brook University School of Medicine, Stony Brook, NY
2009-2019 President, Stony Brook University, Stony Brook, NY
2019- Professor of Medicine, Michigan State University College of Human Medicine, East Lansing, MI
2019-  President, Michigan State University, East Lansing, MI


Year(s) Appointment
1987-2006 Attending physician, Internal Medicine and Infectious Diseases, Barnes-Jewish Hospital of St. Louis 
Chief Medical Consultant, BarnesCare Travelers Clinic
1989 Chairman, Committee to Formulate a Health Policy for Washington University Personnel Who Work with Animals
1992-2000 Member, Washington University MA/MD Committee
1992-2001 Program Committee, American Society of Tropical Medicine and Hygiene
1995-1997 At-large Representative Washington University Faculty Senate
Member, Senate Council of Washington University
Member, Advisory Committee on Academic Freedom and Tenure
1997-1999 Faculty Representative, Washington University Benefits Committee
1999-2004  Selection Committee and Advisory Board Medical Student International Fellowships
2000-2002 Clinical Representative to the Executive Faculty, Washington University School of Medicine
2000-2004 Chairman, Institutional Biological and Chemical Safety Committee
2001-2002 Division of Biology and Biomedical Sciences Graduate Admissions Committee
2006-2008 Chairman, Research Strategic Planning for Washington University School of Medicine
2007-2009 Chairman, Skandalaris Center Research Planning Committee
2009-2019 Governing Body, Stony Brook University Hospital, Stony Brook NY


Massachusetts License 1980-83

Missouri License 1983-present

American Board of Internal Medicine, Certification in Internal Medicine 1983

American Board of Internal Medicine, Certification in Infectious Diseases 1986




Year(s) Honor/Award
1976 Honors in Biological Sciences, University of Chicago
1976 Phi Beta Kappa, University of Chicago
1979 Albert Schweitzer Fellow of Harvard Medical School 
1985-1988 Pfizer Postdoctoral Fellow
1994-1999 Research Career Development Award, NIH
1999-2004 Burroughs-Wellcome Scholar in Molecular Parasitology
2000 Distinguished Service Teaching Award — Washington University School of Medicine
2002-2004 Permanent member, Tropical Medicine and Parasitology Study Section
2004-2006 Permanent member, Eukaryotic Pathogenesis Study Section
2005-2006 Excellence in Mentoring, Washington University School of Medicine
2006 Distinguished Service Award, Washington University Medical Center Alumni Association
2007-2008 Ambassador, Paul G. Rogers Society for Global Health Research
2009 Honorary Doctorate Degree, Konkuk University, Seoul, Korea
2009 Honoree, VIBS (Victims Information Bureau of Suffolk)
2010 Long Island Association Small Business Education Advocate Award
2010 Thomas Hartman Humanitarian Award
2010 The Influentials: “Long Island Business News” Top 20 Agents of Change
2012 Three Village Man of the Year
2012, 2013, 2015, 2016 “Long Island Press,” Best College President
2013 David Award Honoree
2014 EOP (Educational Opportunity Program) Champion
2014 American Heart Association Distinguished Leadership Honoree


Year(s) Position
2006-2009 Board of Directors, Center for Emerging Technologies
2006-2009 Board Member, Research Alliance of Missouri
2006-2009 Board of Trustees, Saint Louis Academy of Science
2007-2009 Board Member, St. Louis Center of Excellence, Missouri Life Sciences Trust Fund
2009-2017 Board of Trustees, Cold Spring Harbor Laboratory
2009-2017 Board of Directors, Goodwill Industries of Greater NY and Northern NJ
2009-2018 Board of Directors, The Research Foundation of SUNY
2009-2019 Board of Directors, Long Island Association
2010- Education Working Group member for United States Senator Kirsten Gillibrand
2011 Health and Education Transition Committee member for NY Governor Andrew Cuomo
2011-2019 Long Island Regional Economic Development Council
2012-2019 Board of Directors, Accelerate Long Island
2013-2019 Board of Directors, New York Genome Center
2014-2017 Chair, Long Island Regional Advisory Council on Higher Education


National Science Advisory Board for Biosecurity (NSABB), Criteria Roundtable Adviser, June 2006

NIH Blue Ribbon Panel on the National Emerging Infectious Diseases Laboratories, 2008-2010

NIH National Advisory Allergy & Infectious Diseases Council, 2008-2012

US Department of Commerce, Emerging Technology and Research Advisory Committee, 2008-2010

Chair, Board of Directors, Brookhaven Science Associates, 2009-2019

National Security Higher Education Advisory Board, 2011-2018

Chair, National Science Advisory Board for Biosecurity (NSABB), 2012-2018

Association of Public and Land-Grant Universities, Board of Directors, 2012-2016, 2019-

Association of Public and Land-Grant Universities, Research Intensive Committee, Vice Chair, 2017-

Chair, America East Conference Board of Presidents, 2012-2015

America East Conference Board of Presidents, 2009-2019 

Chair, Universities Research Association Council of Presidents, 2014-2015

National Collegiate Athletic Association (NCAA) Division I Board of Directors, 2014-2018

National Collegiate Athletic Association (NCAA) Division I Board of Governors, 2016-2018

Association of Public and Land-Grant Universities, Research Intensive Committee, Vice Chair, 2016-2018, Chair 2019-

UNWomen HeForShe Champion: One of 10 university leaders worldwide (and one of the two in the United States) appointed by UNWomen as Global Champions

NCAA Board of Directors Pathway Program Presidential Mentor, 2017-2019

NCAA Board of Governors Student Athlete Engagement Committee, 2017-2018

Association of American Universities Board of Directors, 2017-

NIH Advisory Committee to the Director, Working Group on Foreign Influences on Research Integrity, 2018-2019


Associate Member, American College of Physicians, 1981

Member, American Society of Tropical Medicine and Hygiene, 1988

Member, Infectious Disease Society of America, 1989

Member, American Federation for Clinical Research, 1989

Member, American Society for Microbiology, 1992

Fellow, Infectious Disease Society of America, 1995

Member, American Society for Clinical Investigation, 1995

Secretary-Treasurer, Board of Directors, Infectious Diseases Society of St. Louis, 2004-2007 


Editorial Board:

Infection and Immunity 1998-2003

Ad hoc reviewer for:

New England Journal of Medicine

Clinical Infectious Diseases

Journal of Infectious Diseases

Molecular Microbiology


Physiological Reviews

Cellular Microbiology


Acta Tropica


Parasite Immunology

Experimental Parasitology


Journal of Parasitology

Am.J.Tropical Medicine and Hygiene

Laboratory Animal Science

Molecular and Biochemical Parasitology


Ad hoc grant reviewer for:

Wellcome Trust

International Center for Diarrhoeal Disease Research


American Federation for AIDS Research NIH—SEPs on TDRU program

Temporary member: NIH-TMP study section 10-2000, 6-2002

EpScor NSF Site Visit Team 2005

Educational Accreditation:

Chair, University of California, Santa Cruz accreditation team for Western Association of Schools & Colleges (WASC), 2015


Newsday: Stanley: Protect research institutions from sequestration – and beyond, October 2012

Newsday: How will the sequester affect you?  Long Island Institutions respond, February 2013

Huffington Post: College Cost and Student Loan Debt, June 2013

Huffington Post: Federal Investment in Research Still Essential  April 2014

Huffington Post:  70 Years After the GI Bill, We Need a Similar Investment, June 2014

Newsday: A sure way to attack deadly Ebola, September 2014

Huffington Post: Protect and Maintain America's Scientific Preeminence, December 2014 

Huffington Post: Investing in America's Dazzling Scientific Talent, December 2014 

Huffington Post: How Best to Hold Federal Scientific Research Accountable, January 2015 

Huffington Post: The Changing Politics and Consistent Science of Vaccinations, March 2015

Scientific American: Give Young Scientists the Keys to the Lab, October 2015

Huffington Post: HeForShe Comes to Campus, April 2016

Huffington Post: Fixing Our National Infrastructure Requires Fixing Our Science Infrastructure, October 2016

Scientific American: Anti-Immigration Rhetoric Is a Threat to American Leadership, March 2017

Inside Higher Ed: Focus on Economic Mobility, January 2018

Chronicle of Higher Education: How to Help Combat Global Warming, Campus by Campus, August 2018


Visiting scientist and lecturer — Centro de Investigacion y de Estudios Avanzados del IPN, Mexico City, Mexico, March 1991

Speaker — “Molecular approach to Entamoeba histolyticapathogenesis,” St. Louis University, April 1991

Chair — Amebiasis Session, American Society Tropical Medicine Hygiene — “Isolation of an Entamoeba histolyticacDNA clone encoding a protein with a zinc finger domain,” Boston, November, 1991

Keynote Speaker — “Role of the amebic cysteine proteinase in amebic liver abscess formation.” Meeting of the Society of Biological Chemistry (Mexico), Zacetecas, Mexico, November 1994

Co-chair and Speaker — Merck Symposium on Amebiasis — “New models for amebiasis.” ASTMH Meetings, Cincinnati, November 1994

Speaker — “Scid mouse model of amebiasis” and “Scid mice and gene knockout mice as models for parasitic disease.” India/USA. Joint Vaccine Action Program, Lucknow, India, December 1994

Speaker — “What can murine models tell us about the immunobiology of amebiasis?” Berne Immunology Center, University of Virginia, Charlottesville, December 1994

Speaker — “Progress in a vaccine for amebiasis.” European Conference on Tropical Medicine, Hamburg, November 1995

Chair and Speaker — Symposium — New insights into the immunobiology of parasitic diseases from knockout and scid mice. ASTMH Meeting, December 1996

Speaker — Bernardo Sepulveda Molecular Biology Seminar, XIII Congress on Amebiasis, Mexico City, Mexico, January 1997

Speaker — Keystone Symposium on Cellular and Molecular Cross Talk at Mucosal Surfaces, Santa Fe, New Mexico, March 1997

Speaker — “EhADH2 enzyme: A novel target for anti-amebic drugs.” ICTDR Conference, Washington, DC, April 1997

Speaker — “Oral and DNA vaccines to prevent amebiasis.” ICTDR Conference, Washington, DC. April 1998

Speaker — “How intestinal epithelial cells regulate the inflammatory response to enteric pathogens.” University of Texas Health Sciences Center, San Antonio, Texas, June 1998

Visiting professor and Speaker — “Amebiasis: Putting man into mouse to understand an ancient enemy.” New York University Medical Center Grand Round, January 1999

Speaker — “Pathways for amebic induction of inflammation and programmed cell death,” Burroughs Wellcome

Symposium, ASTMH Meeting, Washington, DC, November 1999

Speaker — “Pathways for amoebic induction of inflammation and tissue damage.” International
Symposium on Amoebiasis. Hamburg, Germany, July 2000

Speaker — National Institutes of Health/National Institute for Allergic and Infectious Diseases, “Amebic dysentery and ICE,” April 2001

Speaker — St. Louis University, “Amebic dysentery and ICE,” September, 2001

Speaker — University of Texas at El Paso, “Amebic dysentery and ICE,” October 2001

Speaker — Southern Illinois University at Carbondale, “Amebic dysentery and ICE,” October 2001

Speaker — Washington University School of Medicine, Department of Pediatrics Grand Rounds, “Amebiasis — New insights into an ancient enemy,” October, 2001

Chairman and Speaker: Session on Amebiasis: Ellison Foundation Conference on Tropical Diseases, Bhubaneswar, India, February 2002

Speaker — Woods Hole Tropical Medicine and Parasitology Course: “Amebiasis”, July 2002, July 2003.

Speaker — Plenary Session, X International Conference on Parasitology, Vancouver, B.C. “Pathways for amebic induction of inflammation and programmed cell death,” August 2002.

Speaker — Special Symposium in Honor of Jean Hickman: “New insights into amebiasis from SCID-HU-INT mice.” ASTMH meeting, Denver, November 2002

Speaker — “Role of TNF in amebic induced inflammation.” EMBO Conference on Amebiasis, Paris, France, March 2003

Speaker — Engineering Connections Series — “SARS and other emerging infectious diseases — the dangers of a small world.” Washington University, September 2003

Speaker — Yonsei University, Challenges in the Post Genomic Era: “Simultaneous host/pathogen genomics,” November 2003

Speaker — Korean Society of Parasitology: “Pathways for amebic induction of inflammation and programmed cell death,” November 2003

Speaker — Institute Pasteur: “New insights into dysentery from SCID-HU-INT mice,” November 2003

Speaker — University of Illinois, Emerging Infectious Diseases Conference: “Pathogenesis of amebiasis,” March 2004

Speaker — University of Pennsylvania, Parasitology Group: “Understanding amebiasis from the host and pathogen perspective,” November 2004

Speaker — Washington University School of Medicine, Medical Grand Rounds: “Emerging Infectious

Diseases — Preparing for the Unexpected and the Inevitable,” November 2004

Speaker — 7th Annual Conference on Hemophilia, San Juan, Puerto Rico, “Emerging Infections—Preparing for the unexpected and the inevitable,” February 2005

Speaker — NIAID/NIDDK workshop on Humanized Mouse Models of Disease. Washington, DC

Speaker — ASM Biodefense Meeting, Washington DC: “Chimeric SCID-Human Mice to Study Enteric Pathogens,” February 2006

Speaker — MMI/ID Seminar Series: “Molecular Dissection of Entamoeba histolytica Pathogenesis,” March 2006

Speaker — Washington University Reunion Medical Update: “Avian Influenza and Emerging Infectious Diseases,” May 2006

Speaker — Washington University Reunion College: “The Threat of Emerging Infectious Diseases, Avian Influenza and Beyond,” May 2006

Speaker — Pathobiology of human diseases series: Biodefense and the immunogenetics of smallpox vaccination. Washington University, May 2007

Speaker — IGCC-Public Policy and Biological Threats: Training the Next Generation; “Basics of Viral Pathogenesis and Disease.” La Jolla, California, July 2007.

Speaker — 13th Annual Kentucky EPSCoR Statewide Conference. “Perspectives and lessons-learned in building academic team science.” Lexington, Kentucky, October 2007

Speaker — 5th Annual MRCE Meeting, Washington University. “Immunogenetics of Smallpox Vaccination.” St. Louis, MO, October 2007

Speaker — IGCC-Public Policy and Biological Threats: Training the Next Generation; “Basics of Viral Pathogenesis and Disease.” La Jolla, California, July 2008

Speaker — Institute for Public Health, International Public Health Activities at Washington University in St. Louis; Washington University, September 2008

Speaker — Tradeline, Inc., Academic Medical & Health Science Centers 2008; “Key program and facility initiative to grow disease-focused research and funding.” San Francisco, California, October 2009

Speaker — “Fueling Local Economies: Research, Innovation and Jobs,” U.S. Congress Joint Economic Committee Hearing, Washington, DC, June 2010

Speaker — “Challenges for Public Education in the United States and China,” Zuel University, Wuhan, China, April 2011

Speaker – APLU Panel “Continuing Research Amidst Fiscal Restraint,” November 2012 

Speaker — Gain-of-Function Research on Highly Pathogenic Avian Influenza H5N1 Viruses: An International Consultative Workshop, Washington, DC, December 2012

Speaker — Dual Use Research of Concern, CICG, Geneva, Switzerland, February 2013

Speaker — AAAS-AAU-APLU-FBI meeting – Setting the Stage: Biological Research in Today’s Global Research Environment, Washington, DC, February 2013 

Speaker — National Institutional Biosafety Committees Conference, Seattle, June 2013

Speaker — APLU Annual Meeting — “Working with State Governments: Understanding Higher Education Budgets to Maximize Investments,” November 2014

Speaker — Adelphi University — “Ebola and Beyond: Are We Ready?” November 2014 Presentation — National Science Advisory Board for Biosecurity (NSABB); National Research Council and Institute of Medicine of the National Academies, December 2014 

Speaker — AAU Panel “Sustaining the Biomedical Research Enterprise: Mapping a Course for the Future,” April 2015

Speaker — New York State Department of Health Commissioner Medical Grand Rounds: “Mosquito-Borne Infectious Diseases: The Next Frontier,” September 2016

Speaker — SXSWedu Panel — “A Gender Lens: Evolving Equality in Education,” March 2017

Speaker — ACE Panel — “Evolving Gender Equality in HE: University Champions and the United Nations HeForShe Movement,” March 2017

Keynote Speaker — SUNY Undergraduate Research Conference (SURC) — “Far Beyond Test Tubes — The Extraordinary Impact of University Research and Why It Greatly Increases the Value of Your Education,” April 2017

Speaker — G7 University Education for All Conference, Udine, Italy, June 2017

Panelist — NCAA Presidential Panel, Student Athlete Health & Safety Issues, January 2018 

Panelist — UC3 Conference, “Setting the Vision and Strategy for Neutrality,” February 2018

Panelist — HeForShe Progress Report: Stories from Four Continents, September 2017

Panel Moderator — APLU Council of Presidents Meeting — “Discussion with FBI: Security Concerns and Research Universities,” June 2018

Panel Moderator — FBI Academia Summit — Preventing, Mitigating and Combating Threats and Risks, September 2018

Panelist — HeForShe Impact Summit, Ending Gender-Based Violence, September 2018

Panelist — Association of Academic Health Centers, “Future of the Relationship between the AHC and the University,” October 2018

Panelist — NAFSA Presidential Panel, Internationalization of Higher Education, November 2018

Speaker — Medical Grand Rounds — “Living with Uncertainty: The Challenge of Dual Use Research and Synthetic Biology,” January 2019

Panelist — American Council on Education (ACE) Annual Meeting, “Science, Security, and Foreign Influence: Insights from Federal Agencies and Higher Education Leadership,” March 2019


Principal Investigator, U54 AI057160-01, “Midwest Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research,” 9/1/03 to 3/1/14, Direct costs: $5,123,000/year

Principal Investigator, NIAID R01 AI-30084, "Molecular Dissection of Entamoeba histolytica pathogenesis,” 7/01/95 to 1/31/2011, Direct costs: $250,000

Co-Investigator, 1UL1RR024992-01 (Kenneth Polonsky, M.D. Principal Investigator) Washington University Institute of Clinical and Translational Sciences (CTSA), Co-Director, Tracking and Evaluation Program, 9/17/07 to 5/31/12, Annual funds $6,818,890

Principal Investigator, Pathways of inflammation and tissue damage in amebiasis. Burroughs Wellcome Scholar in Molecular Parasitology, 7/1/99 to 6/30/06, Total direct costs: $425,000

Principal Investigator, NIAID R01 AI-51621-01, “Structure-Function of Entamoeba alcohol dehydrogenase 2,” 5/01/02 to 3/31/06, Direct costs $200,000/year

Principal Investigator, 1C06RR029841-01, “An Animal Biosafety Level 3 Laboratory for Stony Brook University,” 3/25/10 to 6/30/15, NIH National Center for Research, $14,179,569


Principal Investigator, NSF, Leveraging SUNY LSAMP to Build Better STEM Pathways and Prepare Global STEM Scholars, 7/2011 to 7/2016, Total Award Amount: $2,521,815

Principal Investigator, NSF, The State University of New York (SUNY) LSAMP:  Meeting the Grand Challenge of Preparing Students for Successful Transitions into STEM Majors and Beyond, 9/2016 to 9/2021, Total Award Amount: $4 million


Attending physician, Red Medical Service, Barnes Hospital, 1989 to 2007

Attending physician, Infectious Diseases Service, Barnes — Jewish Hospital, 1987 to 2007

Chief Medical Consultant, BarnesCare Travelers Clinic, 1990 to 2009


Lecturer, Washington University School of Medicine, 1st-Year Course in Microbiology “Introduction to Tropical Medicine”

Lecturer, Washington University School of Medicine, 2nd-Year Course in Pathophysiology of Infectious Diseases “Bacteremia and Sepsis,” “Protozoa I, Protozoa III,” and “Cases in Tropical Medicine” 

Lecturer, Infectious Diseases and the Diagnostic Laboratory Course, “Intestinal Protozoa”

Lecturer, Clinical Infectious Diseases Course, “Diarrheal Diseases,” “Diseases of Travelers,” “Bacteremia and Sepsis,” and “Tropical Diseases” 

Lecturer, Lucille P. Markey Special Emphasis Pathway in Human Pathobiology, “Vaccines for Malaria”

Lecturer, Microbial Pathogenesis Course, “MDR genes and pathogenesis”

Lecturer, Molecular Mechanisms of Disease Course, “Vaccines against parasitic diseases”

Instructor, “Case Problems in Cell Biology and Biochemistry”

Instructor, Tropical Medicine Course

Faculty advisor, International Health and Tropical Medicine Forum

Lecturer, Barnes Housestaff Conference, “Diseases of Travelers”

Lecturer, Microbiology 1st year Graduate Student Course, “Protozoan taxonomy and diversity”

Lecturer, Honors Class, “The Global Challenge of Infectious Diseases,” Fall 2012, Stony Brook University

Lecturer, Honors Class, “The 21st Century University,” Fall 2013, Stony Brook University

Lecturer, Honors Class, “The Continuing Challenge of Infectious Diseases,” Spring 2015, Stony Brook University

Lecturer, Honors Class, “Continuing Global Challenges of Infectious Diseases,” Spring 2016, Stony Brook University

Lecturer, Honors Class, “The Continuing Global Challenges of Infectious Diseases: From Anthrax to Zika,” Spring 2017, Stony Brook University

Lecturer, Honors Class, “The Continuing Global Challenges of Infectious Diseases: From Anthrax to Zika,” Spring 2018, Stony Brook University

Lecturer, Honors Class, “Continuing Global Challenges of Infectious Diseases: From Anthrax to Zika,” Spring 2019, Stony Brook University



1.     Wong, YC; Stanley Jr, SL; Garber, BB. Separation and characterization of neuronal and glial cell populations from embryonic chick cerebra in culture. Anatomischer Anzeiger, 1981; 150:351-373.

2.    Stanley Jr, SL; Kehl, O. Ascending paralysis associated with diethylcarbamazine treatment of a M. loa loa infestation—A case report and review of the literature. Tropical Doctor, 1982; 12:16-19.

3.    Stanley Jr, SL; Lusk, R. Thoracic actinomycosis presenting as a brachial plexus syndrome. Thorax, 1985: 40:74-75.

4.    Powderly, WG; Stanley Jr, SL; Medoff, G. Pneumococcal endocarditis: Report of a series and review of the literature. Review of Infectious Diseases, 1986; 8:786-789.

5.    Stanley Jr, SL; Bischoff, JK; Davie, JM. Antigen induced rheumatoid factors: Protein and carbohydrate antigens induce different rheumatoid factor responses. Journal of Immunology, 1987; 139:2936-2942.

6.    Stanley Jr, SL; Li, E; Davie, JM. Antigen induced rheumatoid factors: Characterization of monoclonal rheumatoid factors produced after protein and carbohydrate immunization. Molecular Immunology, 1988; 25:285-291.

7.     Li, E; Becker, A; Stanley Jr, SL. Use of Chinese hamster ovary cells with altered glycosylation patterns to define the carbohydrate specificity of Entamoeba histolytica adhesion. Journal of Experimental Medicine, 1988, May; 167(5):17251730. 

8.    Li, E; Becker, A; Stanley Jr, SL. Chinese hamster ovary cells deficient in Nacetylglycosaminyltransferase I activity are resistant to Entamoeba histolytica-mediated cytotoxicity. Infection & Immunity, 1989; 57:812. 

9.    Stanley Jr, SL; Becker, A; Kunz Jenkins, C; Foster, L; Li, E. Cloning and expression of a membrane antigen of Entamoeba histolytica possessing multiple tandem repeats. Proceedings of the National Academy of Sciences of the USA,1990, Jul 1; 87(13):49764980. 

10.  Burch, DJ; Li, E; Reed, S; Jackson, TFHG; Stanley Jr, SL. Isolation of a strain specific Entamoeba histolytica cDNA clone. Journal of Clinical Microbiology, 1991; 29:696701.

11.   Stanley Jr, SL; Jackson, TFHG; Reed, SL; Calderon, J; Kunz Jenkins, C; Gathiram, V; Li, E. Serodiagnosis of invasive amebiasis using a recombinant Entamoeba histolytica protein. JAMA, 1991, Oct; 266(14):19841986. 

12.  Stanley Jr, SL; Foster, L; Phillips, N. Molecular analysis of carbohydrate antigen induced monoclonal IgM antiIgG antibodies (rheumatoid factors). Molecular Immunology, 1992, Apr; 29(4):453-61.

13.  Stanley Jr, SL; Huizenga, H; Li, E. Isolation and partial characterization of a surface glycoconjugate of Entamoeba histolytica. Molecular & Biochemical Parasitology, 1992; 50:127-138.

14.  Stanley Jr, SL; Li, E. Isolation of an Entamoeba histolytica cDNA clone encoding a protein with a putative zinc finger domain. Molecular & Biochemical Parasitology, 1992; 50:185-188. 

15.  Li, E; Kunz Jenkins, C; Stanley Jr, SL. Isolation and characterization of genomic clones encoding a serinerich Entamoeba histolytica protein. Molecular & Biochemical Parasitology, 1992; 50:355-358. 

16.  Cieslak, PR; Stanley Jr, SL. Advances in amebiasis: implications for the clinician. Infectious Diseases in Clinical Practice, 1992; 1(3):151-157.

17.   Zhang, Y; Li, E; Jackson, TFHG; Zhang, T; Gathiram, V; Stanley Jr, SL. Use of a recombinant 170 kDa surface antigen of Entamoeba histolytica in serodiagnosis of amebiasis, and identification of immunodominant domains of the native molecule. Journal of Clinical Microbiology, 1992, Nov; 30(11):2788-2792.

18.  Cieslak, PR; Virgin IV, HW; Stanley Jr, SL. A severe combined immunodeficient (SCID) mouse model for infection with Entamoeba histolytica. Journal of Experimental Medicine, 1992, Dec; 176(6):1605-1609.

19.  Myung, K; Burch, DJ; Jackson, TFHG; Stanley Jr, SL. Serodiagnosis of invasive amebiasis using a recombinant Entamoeba histolytica-antigen based ELISA. Archives of Medical Research, 1992; 23(2):285-288.

20. Zhang, Y; Aley, S; Stanley Jr, SL; Gillin, FD. Cysteine-dependent zinc binding by membrane proteins of Giardia lamblia. Infection & Immunity, 1993; 61:520-524.

21.  Cieslak, PR; Zhang, T; Stanley Jr, SL. Expression of a recombinant Entamoeba histolytica antigen in a Salmonella typhimurium vaccine strain. Vaccine, 1993; 11:773-776.

22.  Zhang, Y; Li, E; Stanley Jr, SL. Entamoeba histolytica: The EHZc3 cDNA clone encodes a zinc-binding protein. Experimental Parasitology, 1993, Aug; 77(1):118-120.

23.  Zhang, T; Cieslak, PR; Foster, L; Kunz-Jenkins, C; Stanley Jr, SL. Antibodies to the serine rich Entamoeba histolytica protein (SREHP) prevent amebic liver abscess in severe combined immunodeficient (SCID) mice. Parasite Immunology, 1994, May; 16(5):225-230.

24.  Zhang, T; Cieslak, PR; Stanley Jr, SL. Protection of gerbils from amebic liver abscess by immunization with a recombinant Entamoeba histolytica antigen. Infection & Immunity, 1994, Apr; 62(4):1166-70.

25.  Yang, W; Li, E; Kairong, T; Stanley Jr, SL. Entamoeba histolytica has an alcohol dehydrogenase homologous to the adhE gene product of Escherichia coli. Molecular & Biochemical Parasitology, 1994; 64:253-260.

26.  Zhang, T; Stanley Jr, SL. Protection of gerbils from amebic liver abscess by immunization with a recombinant protein derived from the 170 kDa adhesin of Entamoeba histolytica. Infection & Immunity, 1994; 62(6):2605-2608.

27.  Li, E; Stenson, WF; Kunz-Jenkins, C; Swanson, PE; Duncan, R; Stanley Jr, SL. Entamoeba histolyticainteractions with polarized human intestinal Caco-2 epithelial cells. Infection & Immunity, 1994; 64(11):5112-5119.

28. Stanley Jr, SL; Tian, K; Koester, JP; Li, E. The serine rich Entamoeba histolytica protein (SREHP) is a phosphorylated membrane protein containing O-linked terminal N-acetylglucosamine (O-GlcNAc) residues. Journal of Biological Chemistry, 1995, Feb; 270(8):4121-4126.

29.  Stanley Jr, SL; Blanchard, JL; Johnson, N; Foster, L; Kunz-Jenkins, C; Zhang, T; Tian, K; Cogswell, FB. Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African Green Monkey. Vaccine, 1995, Jul; 13(10):947-951.

30. Zhang, T; Li, E; Stanley Jr, SL. Oral immunization with the dodecapeptide repeat of the serine rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. Infection & Immunity. 1995, Apr; 63(4):1349-1355.

31.  Stanley Jr, SL; Zhang, T; Rubin, D; Li, E. Role of the amebic cysteine proteinase in amebic liver abscess in severe combined immunodeficient (SCID) mice. Infection & Immunity, 1995, Apr; 63(4):1587-1590.

32.  Velazquez, C; Valette, I; Cruz, M; Labra, M-L; Montes, J; Stanley Jr, SL; Calderon, J. Identification of immunogenic epitopes of the 170-kDa subunit adhesin of Entamoeba histolytica in patients with invasive amebiasis. Journal of Eukaryotic Microbiology, 1995, Sep; 42(5):636-641.

33.  Li, E; Yang, W-G; Zhang, T; Stanley Jr, SL. Interaction of laminin with Entamoeba histolytica cysteine proteinases and its effect on amebic pathogenesis. Infection & Immunity. 1995, Oct; 63(10):4150-4153.

34.  Flores, BM; Stanley Jr, SL; Yong, TS; Ali, M; Diedrich, DL; Torian, BE. Surface localization, regulation, and biologic properties of the 96-kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic Entamoeba histolytica. Journal of Infectious Diseases, 1996, Jan; 173(1):226-231.

35.  Yong, TS; Li, E; Clark, D; Stanley Jr, SL. Complementation of a Escherichia coli adhE mutant by the Entamoeba histolyticaEhADH2 gene provides a method for the identification of new anti-amebic drugs. Proceedings of the National Academy of Sciences of the USA, 1996, Jun 25; 93(13):6464-6469.

36.  Seydel, KB; Braun, K; Zhang, T; Jackson, TFHG; Stanley Jr, SL. Human anti-amebic antibodies provide protection against amebic liver abscess formation in the SCID mouse. The American Journal of Tropical Medicine & Hygiene, 1996; 55:330-332.

37.  Zhang, T; Stanley Jr, SL. Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serine rich Entamoeba histolytica protein induces an anti-amebic immune response and protects gerbils from amebic liver disease. Infection & Immunity, 1996, May; 64(5):1526-1531.

38.  Seydel, KB; Li, E; Stanley Jr, SL. Human intestinal epithelial cells produce pro-inflammatory cytokines in response to infection in a SCID-HU-INT model of amebiasis. Infection & Immunity, 1997, May; 65(5):1631-1639.

39.  Lotter, H; Zhang, T; Seydel, KB; Stanley Jr, SL; Tannich, E. Identification of an epitope on the Entamoeba histolytica 170 kDa-lectin conferring antibody mediated protection against invasive amebiasis. Journal of Experimental Medicine, 1997, May 19 185(10):1793-1801.

40. Ryan, ET; Butterton, JR; Zhang, T; Stanley Jr, SL; Calderwood, SB. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti-V. cholerae antibody responses in mice. Infection & Immunity, 1997, Aug; 65(8):3118-3125.

41.  Seydel, KB; Zhang, T; Stanley Jr, SL. Neutrophils play a critical role in early resistance to amebic liver abscess in SCID mice. Infection & Immunity, 1997, Sep; 65(9):3951-3953.

42.  Zhang, T; Stanley Jr, SL Expression of the serine rich Entamoeba histolytica protein (SREHP) in the avirulent vaccine strain Salmonella typhi TY2x4297 cya crp asd: Safety and immunogenicity in mice. Vaccine, 1997, Aug-Sep; 15(12-13): 1319-1322.

43.  Marinets, A; Zhang, T; Guillen, N; Gounon, P; Bohle, B; Vollman, U; Scheiner, O; Wiedermann, G; Stanley Jr, SL; Duchene, M. Protection against invasive amoebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica. Journal of Experimental Medicine, 1997; 186:1557-1565.

44.  Wang, L; Calderon, J; Stanley Jr, SL. Identification of B cell epitopes in the serine rich Entamoeba histolytica protein. The American Journal of Tropical Medicine & Hygiene, 1997, Dec; 57(6):723-726.

45.  Stanley Jr, SL; Jackson, TFHG; Foster, L; Singh, S. Longitudinal study of the antibody response to recombinant Entamoeba histolytica antigens in patients with amebic liver abscess. The American Journal of Tropical Medicine & Hygiene, 1998, Apr; 58(4):414-416.

46.  Sultan, F; Jin-L-l; Jobling, MG; Holmes, RK; Stanley Jr, SL. Mucosal immunogenicity of a holotoxin-like molecule containing the serine rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infection & Immunity, 1998, Feb; 66(2):462-468.

47.  Seydel, KB; Zhang, T; Champion, GA; Fichtenbaum, C; Swanson, PE; Tzipori, S; Griffiths, JK; Stanley Jr, SL. Cryptosporidium parvum infection induces human TNF and IL-8 production from human intestinal xenografts in SCID mice. Infection & Immunity, 1998; 66:2379-2398.

48. Seydel, KB; Stanley Jr, SL. Entamoeba histolytica induces host cell death in amebic liver abscess by a non-Fas, non-TNF-dependent pathway of apoptosis. Infection & Immunity, 1998 Jun; 66(6):2980-2983.

49.  Seydel, KB; Li, E; Zhang, Z; Stanley Jr, SL. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. Gastroenterology,1998, Dec; 115(6):1446-1453.

50.  Temesvari, LA; Harris, EN; Stanley Jr, SL; Cardelli, JA. Early and late endosomal compartments of Entamoeba histolytica are enriched in cysteine proteinases, acid phosphatases and several Ras-related Rab GTPases. Molecular & Biochemical Parasitology, 1999; 103:225-241.

51.  Zhang, T; Stanley Jr, SL. DNA vaccination with the serine rich Entamoeba histolytica protein (SREHP) prevents amebic liver abscess in rodent models of disease. Vaccine, 1999, Dec 10; 18(9-10):868-874.

52.  Seydel, KB; Smith, SJ; Stanley Jr, SL. Interferon-gamma and nitric oxide are required for host defense in a murine model of amebic liver abscess. Infection & Immunity, 2000; 68:400-402.

53.  Lotter, H; Khajawa, F; Stanley Jr, SL; Tannich, E. Protection of gerbils from amebic liver abscess by vaccination with a 25 mer peptide derived from the “cysteine-rich” region of the Entamoeba histolytica galactose-specific adherence lectin. Infection & Immunity, 2000; 68:4416-4421.

54.  Zhang, Z; Yan, L; Wang, L; Seydel, KB; Li, E; Ankri, S; Mirelman, D; Stanley Jr, SL. Emtamoeba histolytica cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amebiasis. Molecular Microbiology, 2000, Aug; 37(3):542-548.

55.  Zhang, Z; Jin, L; Champion, G; Seydel, KB; Stanley Jr, SL. Shigella infection in SCID-HU-INT mice: role for neutrophils in containing bacterial dissemination in human intestine. Infection & Immunity, 2001; 69:3240-3247.

56.  Stenson, W; Zhang, Z; Riehl, T; Stanley Jr, SL. Amebic infection induces cyclooxygenase-2 (COX-2) production in human intestine. Infection & Immunity, 2001; 69:3382-3388.

57.  Espinosa, A; Yan, L; Zhang, Z; Foster. L; Clark, D; Li, E; Stanley Jr, SL. The bifunctional Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) protein is necessary for amebic growth and survival and requires an intact C-terminal domain for both alcohol dehydrogenase and acetaldehyde dehydrogenase activity. Journal of Biological Chemistry, 2001, Jun 8; 276(23):20136-20143.

58.  Babcock, HM; Ritchie, DJ; Christiansen, E; Starlin, R; Little, R; Stanley Jr, SL. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clinical Infectious Diseases, 2001, May 1; 32(9):1373-1375.

59.  Yan, L; Stanley Jr, SL. Blockade of caspases inhibits amebic liver abscess formation in a mouse model of disease. Infection & Immunity, 2001; 69:7911-7914.

60. Zhang, Z; Duchene, M; Stanley Jr, SL. A monoclonal antibody to the amebic lipophosphoglycan/proteophosphoglycan antigens can prevent disease in human intestinal xenografts infected with Entamoeba histolytica. Infection & Immunity, 2002; 70:5873-5876.

61.  Zhang, Z; Mahajan, S; Zhang, X-C; Stanley Jr, SL. Tumor necrosis factor-α is a key mediator of the gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. Infection & Immunity, 2003; 71:5355-5359.

62.  Zhang, X-C; Zhang, Z; Alexander D; Bracha, R; Mirelman, D; Stanley Jr, SL. Expression of  amoebapores is required for full expression of Entamoeba histolytica virulence in amebic liver abscess, but is not necessary for the induction of inflammation or tissue damage in amebic colitis. Infection & Immunity, 2004; 72:678-683.

63.  Zhang, Z; Stanley Jr, SL. Stereotypic and specific elements of the human colonic response to Entamoeba histolytica and Shigella flexneri infection. Cellular Microbiology, 2004, Jun; 6(6):535-564.

64.  Espinosa, A; Clark, DC; Stanley Jr, SL. Entamoeba histolytica Alcohol Dehydrogenase 2 (EhADH2) as a target for antiamoebic agents. Journal of Antimicrobial Chemotherapy, 2004, Jul; 54(1):56-59.

65.  Chen, M; Li, E; Stanley Jr, SL. Structural analysis of the acetaldehyde dehydrogenase activity of Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2), a member of the ADHE enzyme family. Molecular & Biochemical Parasitology, 2004; 137:201-205.

66.  Davis, PH; Zhang, Z; Chen, M; Zhang, XC; Chakraborty, S; Stanley Jr, SL. Identification and characterization of a family of Bsp-A like surface proteins of Entamoeba histolytica with novel leucine rich repeats. Molecular & Biochemical Parasitology, 2006; 145:111-116.

67.  Pelosoff, L; Davis, PH; Zhang, Z; Zhang, XC; Stanley Jr, SL. Coordinate but disproportionate activation of apoptotic, regenerative, and inflammatory pathways characterizes the liver response to acute amebic infection. Cellular Microbiology, 2006, Mar; 8(3):508-522.

68. Stanley Jr, SL. The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious disease. Seminars in Hematology, 2006, Apr; 43(3) Supplement: S17-S22.

69.  Davis, P; Zhang, X; Guo, J; Townsend, RR; Stanley Jr, SL. Comparative proteomic analysis of two Entamoeba histolytica stains with different virulence phenotypes identifies peroxiredoxin as an important component of amebic virulence. Molecular Microbiology, 2006; 61:1523-1532.

70.  Ludlam, CA; Powderly, WG; Bozzett, S; Diamond, M; Koerper, MA; Kulkarni, R; Ritchie, B; Siegel, J; Simmonds, P; Stanley Jr, SL; Tapper, ML; von Depka, M. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet, 2006, Jan 21; 367(9506):252-261.

71.   Davis, PA; Schulz, J; Stanley Jr, SL. Transcriptomic comparison of two Entamoeba histolytica stains with defined virulence phenotypes identifies new virulence factor candidates and key differences in the expression patterns of cysteine proteases, lectin light chains, and calmodulin. Molecular & Biochemical Parasitology, 2007, Jan; 151(1):118-128.

72.  Stanley Jr, SL; Frey, SE; Taillon-Miller, P; Guo, J; Miller RD; Koboldt, DC; Elashoff, M; Christensen, R; Saccone, NL; Belshe, RB. The Immunogenetics of Smallpox Vaccination. Journal of Infectious Diseases, 2007, Jul 15; 196(2): 212-219.

73.  Lawrence, SJ; Lottenbach, KR; Newman, FK; Buller, RM; Bellone, CJ; Chen, JJ; Cohen, GH; Eisenberg, RJ; Belshe, RB; Stanley Jr, SL; Frey, SE. Antibody response to vaccinia membrane proteins after smallpox vaccination. Journal of Infectious Diseases, 2007; 196(2):220-229.

74.  Melendez-Lopez SG; Herdman, S; Hirata K; Choi, MH; Choe, Y; Craik, C; Caffrey, CR; Hansell, E; Chavez-Munguia, B; Chen, YT; Roush, WR; Mckerrow, J; Eckmann, L; Guo, J; Stanley Jr, SL; Reed, SL. Use of recombinant Entamoeba histolyticacysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. Eukaryotic Cell, 2007, Jul; 6(7):1130-1136.

75.  Bullok, KE; Maxwell, D; Kesarwala, AH; Gammon, S; Prior, JL; Snow, M; Stanley, S; Piwnica-Worms, D. Biochemical and in vivo characterization of a small membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry, 2007, Apr 3; 46 (13): 4055-4065.

76.  Snow, M; Chen, M; Guo, J; Atkinson, J; Stanley Jr, SL. Differences in complement mediated killing of Entamoeba histolytica between men and women—an explanation for the increased susceptibility of men to invasive amebiasis? American Journal of Tropical Medicine and Hygiene. 2008, June; 78 (6): 922-923.

77.  Sarder, P; Nehorai, A; Davis, PH; Stanley Jr, SL. Estimating gene signals from noisy microarray images. IEEE Transactions on NanoBioscience. 2008, June, 7(2):142-153.

78.  Sperandio, B., Regnault B., Guo J., Zhang Z, Stanley SL Jr., Sansonetti PJ, Pedron T. Virulent Shigella flexneri subverts the host innate immune response through the manipulation of antimicrobial peptide gene expression. Journal of Experimental Medicine, 2008, 205:1121-32.

79.  Davis, P; Chen, M; Zhang, X; Clark, CG; Townsend, RR; Stanley Jr, SL.  Proteomic Comparison of Entamoeba histolyticaand Entamoeba dispar and the Role of E.histolyticaAlcohol Dehydrogenase 3 in Virulence. PLOS Neglected Tropical Diseases, 2009, 3 (4): e415. Epub 2009 Arp 14. PMID: 19365541

80. Biller L, Davis PH, Tillack M, Matthiesen J, Lotter H, Stanley Jr, SL, Tannich E, Bruchhaus I.  Differences in the transcriptome signatures of two genetically related Entamoeba histolytica cell lines derived from the same isolate with different pathogenic properties.  BMC Genomics 2010 Jan 26;11:63. PMID:  20102605

81.  Otero K, Turnbull IR, Poliani PL, Vermi W, Cerutti E, Aoshi T, Tassi I, Takai T, Stanley Jr, SL, Miller M, Shaw AS, Colonna M.  Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin.  Nat Immunol. 2009 Jul;10(7):734-43 Epub 2009 Jun 7. PMID: 19503107

Reviews and Invited Publications

1.     Stanley Jr, SL; Davie, JM. “Production and function of rheumatoid factors in the normal immune response” Contribution to Microbiology Immunology, 1989; 11:151-187.

2.    Li, E; Stanley Jr, SL. “The role of newer antibiotics in gastroenterology.” Gastroenterology Clinics of North America, 1992; 21: 613-631.

3.    Stanley Jr, SL; Burch, DJ; Cieslak, P. “New diagnostic techniques in amebiasis.” L abMedica International 1992; 9:7-10. 

4.    Stanley Jr, SL. “Amebiasis,” in Conn's Current Therapy. R.E. Rakel, Ed. W.B. Saunders Company, Philadelphia, pp. 60-62, 1993.

5.    Stanley Jr, SL; Li, E. “Pathophysiology of Amebiasis.” Seminars in Gastrointestinal Disease 1993; 4:214-223.

6.    Stanley Jr, SL; Virgin, IV, HW. “Scid mice as models for helminth and protozoan diseases.” Parasitology Today 1993; 9:406-412.

7.     Stanley Jr, SL. "Susceptibility testing and acquired drug resistance in parasitic diseases", in Handbook of Clinical Microbiology, Washington, DC, P. R. Murray, Ed. ASM Press. pp. 1424-1427, 1995.

8.    Li, E; Stanley Jr, SL. “Parasitic diseases of the GI tract.” Current Opinion in Gastroenterology, 1995; 11:63-68.

9.    Li, E; Stanley Jr, SL. “Amebiasis.” Gastroenterology Clinics of North America, 1996; 25:471-492. 

10.  Seydel, K; Stanley Jr, SL. “Scid mouse models for parasitic diseases.” Clinical Microbiology Review, 1996; 9:126-134.

11.   Stanley Jr, SL. “Progress in a vaccine for amebiasis.” Parasitology Today. 1996; 12:7-14.

12.  Sultan, F; Stanley Jr, SL. "Amebiasis" in Current Diagnosis 9, edited by Conn, RB, Borer, WZ, and Snyder, JW. Philadelphia, W.B. Saunders, pp. 225-227, 1997.

13.  Stanley Jr, SL. “Progress towards development of a vaccine for amebiasis.” Clinical Microbiology Review, 1997, Oct; 10(4):637-649.

14.  Stanley Jr, SL. “Malaria vaccines: Are seven antigens better than one?” Lancet 352 (9135):1163-1164), 1998.

15.  Stanley Jr, SL. “Advice to travelers” in Textbook of Gastroenterology, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 1145-1159, 1999.

16.  Stanley Jr, SL. “Advice to travelers” in Atlas of Gastroenterology, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 127-138, 1999.

17.   Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Textbook of Gastroenterology, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 2423-2441, 1999.

18.  Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Atlas of Gastroenterology, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 516-526, 1999.

19.  Stanley Jr, SL. “Prevention of amebiasis and potential of new interventions.” In Amebiasis, edited by Ravdin, J.I. London, Imperial College Press, pp. 137-163, 2000.

20. Stanley Jr, SL; Zhang, T; Seydel, KB. “Animal models of amebiasis.” In Handbook of Animal Models of Infection, edited by Zak, O, and Sande, M. London, Academic Press, pp. 859-865,2000.

21.  Stanley Jr, SL. “Extraintestinal amebiasis.” In Current Therapy for Infectious Diseases, Edited by Schlossberg, D., St. Louis, Mosby, Inc. pp. 693-695, 2001.

22.  Stanley Jr, SL; Li, E. “Amoebiasis.” In Encyclopedia of Life Sciences. London, Macmillan Reference Limited, 2001.

23.  Stanley Jr, SL. “Pathophysiology of amebiasis.” Trends in Parasitology (formerly Parasitology Today). 2001; 17:280-285.

24.  Stanley Jr, SL; Reed, SL. “Entamoeba histolytica: parasite-host interactions.” American Journal of Physiology – Gastrointestinal & Liver Physiology. 2001, Jun; 280: G1049-G1054.

25.  Stanley Jr, SL. “Protective immunity to amebiasis: New insights and new challenges.” Journal of Infectious Diseases, 2001; 184:504-506.

26.  Stanley Jr, SL. “Amebiasis.” Pier Module. 2002. www.pier

27.  Stanley Jr, SL. “Pathways for amebic induction of inflammation and programmed cell death.”  Journal of Parasitology, 2003; 89:S182-S188.

28. Stanley Jr, SL. “Amoebiasis.” Lancet, 2003. 361:1025-34.

29.  Stanley Jr, SL. “Advice to travelers” in Textbook of Gastroenterology, 4th Edition, edited by Yamada,T. Philadelphia, Lippincott-Raven, pp. 1120-1134, 2003.

30. Stanley Jr, SL. “Advice to travelers” in Atlas of Gastroenterology, 3rd Edition, edited by Yamada,T. Philadelphia, Lippincott-Raven, pp. 153-162, 2003.

31.  Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Textbook of Gastroenterology, 4th Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven. pp. 2589-2607, 2003.

32.  Li, E; Stanley Jr, SL. “Parasitic diseases—protozoa” in Atlas of Gastroenterology, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp: 749-760, 2003.

33.  Davis, P; Stanley Jr, SL. “Breaking the species barrier: the use of mouse human chimeras to study human infectious diseases.” Cellular Microbiology, 2003. 5:849-860.

34.  Stanley Jr, SL. “Antiparasitic agents.” In Infectious Diseases, 2nd Edition, edited by Cohen, J., and Powderly, W. London, Mosby, pp. 1941-1960, 2004.

35.  Stanley Jr, SL. “Amebiasis.” In Encyclopedia of Gastroenterology. San Diego, Elsevier, pp. 52-57, 2004.

36.  Stanley Jr, SL. “The Entamoeba histolytica genome: Something old, something new, something borrowed, and sex too?” Trends in Parasitology, 2005, Oct; 21(10):451-3.

37.  Phillips, M; Stanley Jr, SL. “Chemotherapy of protozoal infections.” In Goodman and Gilman’s Pharmacological Basis of Therapeutics, 11th Edition, edited by Lazo, JS, Parker, K, Brunton, LL, Goodman, LS and Gilman, A. New York, McGraw Hill, 2005.

38.  Snow, M; Stanley Jr, SL. “Recent progress in vaccines for amebiasis.” Archives of Medical Research, 2006; 37:280-287.

39.  Stanley, Jr, SL. “Vaccines for amoebiasis: barriers and opportunities.” Parasitology, 2006; 133:S81-86.

40. Stanley Jr, SL.  “Antiparasitic agents” in Infectious Diseases, 3rd Edition, edited by Cohen, J, Powderly, W., Opal, S.M., Mosby, Chapter 150, 2010.

41.  Phillips, M; Stanley Jr, SL. “Chemotherapy of protozoal infections” in Goodman and Gilman’s
Pharmacological Basis of Therapeutics, 12th Edition, edited by Brunton, LL, Chabner, B, Knollmann, B,  New York, McGraw Hill, in press.

42.   Stanley Jr, SL. “Amebiasis and infection with free-living amebas” in Harrison’s Principles of InternalMedicine, 18th Edition, edited by Longo, D., Fauci, A., Kasper, D., Hauser, S., Jameson, J., Loscalzo, J. NewYork, McGraw Hill, 2011.


US Patent 5,130,147: Entamoeba histolytica Immunogenic protein and cDNA clone
Significance: patent of the SREHP cDNA clone; recombinant SREHP is a major vaccine candidate for amebiasis, and a reagent utilized in prototype diagnostic tests.
Inventor: Samuel L. Stanley Jr. and Ellen Li
Assignee: Washington University, St. Louis

US Patent 5,275,935: Amebic glycoconjugate and monoclonal antibody
Significance: patent of the amebic glycoconjugate, a major surface antigen of amebae and a monoclonal antibody, CC 8.6 which recognizes this antigen. Possible uses in diagnostic kits.
Inventor: Samuel L. Stanley Jr. and Ellen Li
Assignee: Washington University, St. Louis

US Patent 5,807,000: Method of screening anti-amebic compounds
Significance: Describes the use of mutant E. coli strains complemented with amebic antigens to screen compounds for anti-amebic activity. 
Inventor: Samuel L. Stanley Jr. 
Assignee: Washington University, St. Louis